Status:
ACTIVE_NOT_RECRUITING
Five Year Oncological Outcome After CME for Sigmoid Colon Cancer
Lead Sponsor:
Nordsjaellands Hospital
Collaborating Sponsors:
Bispebjerg Hospital
Herlev Hospital
Conditions:
Sigmoid Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Study based in existing databases investigating the causal oncological treatment effects of complete mesocolic excision on UICC stage I-III sigmoid colon cancer
Detailed Description
Population-based cohort study, predominantly prospective based, on the same population as our previously study comparing short-term outcome after CME with conventional colon resections. The COMES data...
Eligibility Criteria
Inclusion
- Sigmoid colon cancer was defined as primary adenocarcinomas located in the sigmoid colon (more than 15 cm from the anal verge)
- UICC stage I-III
Exclusion
- Synchronous colorectal cancer - even in the sigmoid colon
- No residual tumor in the specimen after neoadjuvant chemotherapy
- Metachronous colorectal cancer
- Resections in Hillerød not performed according to the principles of CME
- Non-macroradical (R2) resections (peroperative assessment)
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
920 Patients enrolled
Trial Details
Trial ID
NCT03774134
Start Date
June 1 2008
End Date
December 31 2025
Last Update
June 26 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.